Review article: Oesophageal complications and consequences of persistent gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 9, 2004, Pages 47-56

  Pisegna, J ^a,i   Holtmann, G ^b   Howden, C W ^c   Katelaris, P H ^d   Sharma, P ^e   Spechler, S ^f   Triadafilopoulos, G ^g   Tytgat, G ^h  

^a Div of Gastroenterol and Hepatol   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ Div Gastroent/Hepatol (691/111C)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOSCOPY; ESOPHAGUS DISEASE; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HIATUS HERNIA; HIGH RISK PATIENT; HUMAN; MALE; NIGHT; OBESITY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SCREENING; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CHRONIC DISEASE; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 10644221116     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997; 92: S3-S5.
2. Orr WC. Clinical implications of nocturnal gastroesophageal reflux. Pract Gastroenterol 1994; 28: 28A-H.
3. Pisegna JR. GERD and its complications. The pathogenic relationship between symptoms and disease progression. Postgrad Med 2001; 110(3)Spec. no.: 19-23.
4. DeMeester TR, Johnson LF, Joseph GJ, Toscano MS, Hall AW, Skinner DB. Patterns of gastroesophageal reflux in health and disease. Ann Surg 1976; 184: 459-70.
5. Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1981; 26: 65-72.
6. Lillemoe KD, Johnson LF, Harmon JW. Role of the components of the gastroduodenal contents in experimental acid esophagitis. Surgery 1982; 92: 276-84.
7. Rai A, Orlando R. Gastroesophageal reflux disease. Curr Opin Gastroenterol 1998; 14: 326-33.
8. Chang CS, Poon SK, Lien HC, Chen GH. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol 1997; 92: 668-71.
9. Janssens J, Cantrappen G, Peelers T, Ghillbert G. How do 24-h measurements distinguish the disease spectrum of reflux patients? Gastroenterology 1985; 88: 1431.
10. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92; 1293-7.
11. Pisegna JR. Treating patients with acute gastrointestinal bleeding or rebleeding. Pharmacotherapy 2003; 23: S81-S6.
12. Kepczyk T, Cremins JE, Long BD, Bachinski MB, Smith LR, McNally PR. A prospective, multidisciplinary evaluation of premenopausal women with iron-deficiency anemia. Am J Gastroenterol 1999; 94: 109-15.
13. Orlando RC. Reflux esophagitis. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: JB Lippincott, 1991: 1123.
14. Kuo WH, Kalloo AN. Reflux strictures of the esophagus. Gastrointest Endosc Clin N Am 1998; 8: 273-81.
15. Fennerty MB. The continuum of GERD complications. Cleve Clin J Med 2003; 70(Suppl. 5): S33-S50.
16. Dekel R, Morse C, Pass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277-95.
17. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15.
18. Higuchi D, Sugawa C, Shah SH, Tokioka S, Lucas CE. Etiology, treatment, and outcome of esophageal ulcers: a 10-year experience in an urban emergency hospital. J Gastrointest Surg 2003; 7: 836-42.
19. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 1091-8.
20. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002; 47: 2565-73.
21. Spechler SJ. Clinical manifestations and esophageal complications of GERD. Am J Med Sci 2003; 326: 279-84.
22. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-32.
23. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22.
24. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
25. Bonelli L. Barrett's esophagus: results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Endoscopy 1993; 25: 652-4.
26. Winters C Jr, Spurting TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
27. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995; 90: 1053-7.
28. Orr WC, Lackey C, Robinson MG, Johnson LF, Welsh JD. Esophageal acid clearance during sleep in patients with Barrett's esophagus. Dig Dis Sci 1988; 33: 654-9.
29. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92: 27-31.
30. Buttar NS, Falk GW. Pathogenesis of gastroesophageal reflux and Barrett esophagus. Mayo Clin Proc 2001; 76: 226-34.
31. Pass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001; 48: 310-3.
32. Grade A, Pulliam G, Johnson C, Garewal H, Sampliner RE, Pass R. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium. Am J Gastroenterol 1997; 92: 2040-3.
33. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
34. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-5.
35. Falk G. Unresolved issues in Barrett's esophagus in the new millennium. Dig Dis 2000; 18: 27-42.
36. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
37. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-42.
38. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
39. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
40. Graham DY. Helicobacter pylori is not and never was 'protective' against anything, including GERD. Dig Dis Sci 2003; 48: 629-30.
41. Zentilin P, Iiritano E, Vignale C, et al. Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 1057-64.
42. Pandolfino JE, Howden CW, Kahrilas PJ. H. pylori and GERD: Is less more? Am J Gastroenterol 2004; 99: 1222-5.
43. Vaira D, Miglioli M, Mule P, et al. Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut 1994; 35: 309-12.
44. Stolte M. Meining A. Helicobacter pylori and gastric cancer. Oncologist 1998; 3: 124-8.
45. Kim HY, Kim YB, Park CK, Yoo JY, Graham DY. Co-existing gastric cancer and duodenal ulcer disease: role of Helicobacter pylori infection. Helicobacter 1997; 2: 205-9.
46. Adesanya AA, Rocha-Afodu JT, Elesha SO, et al. Gastric acid secretion in Helicobacter pylori positive and negative dyspeptic Nigerians. Niger Postgrad Med J 2001; 8: 61-8.
47. el Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C. McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
48. Wosornu JL. Basal and augmented histamine stimulated acid secretion in Ghanaians. East Afr Med J 1971; 48: 322-6.
49. Solanke TF, Lewis EA. Gastric acid secretion in patients with duodenal ulcer and benign gastric outlet obstruction. Afr J Med Med Sci 1976; 5: 49-53.
50. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003; 98: 1462-70.
51. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. Pylori Study Group. Aliment Pharmacol Ther 1996; 10: 251-61.
52. Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664-8.
53. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999; 94: 3468-72.
54. Koike T, Ohara S, Sekine H. et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 813-20.
55. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64: 526-30.
56. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997; 350: 933.
57. Loffeld RJ, Werdmuller BF, Küster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95-9.
58. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003; 17: 297-305.
59. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
60. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
61. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
62. Bercik P, Verdu E, Armstrong D. Reflux esophagitis and H. pylori. Gastroenterology 1997; 113: 2020-1.
63. McColl KE, el Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000; 29: 687-703, viii.
64. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999; 94: 2840-4.
65. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey. Ann Epidemiol 1999; 9: 424-35.
66. Stene-Larsen G, Weberg R, Froyshov Larsen I, Bjortuft O, Hoel B, Berstad A. Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol 1988; 23: 427-32.
67. Orr W, Heading R, Johnson LF, Kryger M. Sleep and its relationship to gastroesophageal reflux. Aliment Pharmacol Ther 2004; 20(Suppl. 9): 39-46.
68. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
69. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 884-7.
70. Peters FT, Kuipers EJ, Ganesh S, et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999; 13: 921-6.
71. Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004; 126: 980-8.
72. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
73. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-14.
74. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
75. Ouatu-Lascar R, Triadafllopoulos G. Oesophageal mucosal diseases in the elderly. Drugs Aging 1998; 12: 261-76.
76. Gerson LB, Edson R, Lavori PW, Triadafllopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96: 2005-12.
77. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 1252-5.
78. Macdonald CE, Wicks AC, Playford RJ. Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut 1997; 41: 303-7.
79. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
80. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-86.
81. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.